The PD-1 checkpoint inhibitor was approved back in April 2021 ... But for all that, the drug has yet to be much of a money-maker for the company. Despite GSK's predictions of blockbuster status ...

As it turned out, adding spartalizumab to treatment with the two targeted drugs failed to provide ... to market well behind other PD-1/PD-L1 checkpoint inhibitors – that piggybacking on its ...

Researchers from Zhejiang Jieyuan Med-Tech Co. Ltd. and collaborators have reported the design and preclinical characterization of a novel series of benzylamine derivatives acting as PD-1/PD-L1 ...

Aurigene Oncology Ltd. has divulged compounds acting as dual antagonists of adenosine receptor A2A (ADORA2A) and programmed cell death 1 ligand 1 (CD274; PD-L1) reported to be useful for the treatment ...